Celebrating 25 years Est 1999-2024
*Across 3 years $3395.52 only $1697.76
AbbVie Completes Acquisition of Cerevel Therapeutics PR Newswire NORTH CHICAGO, Ill., Aug. 1, 2024 Cerevel's clinical-stage assets complement...
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a...
Kuehn Law Encourages MDC, WAVD, NS and CERE Investors to Contact Law Firm PR Newswire NEW YORK, Jan. 24, 2024...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.